Infusional 5-fluorouracil, cisplatin and mitomycin C in advanced gastric cancer: a low cost effective regimen (Q33341264)

25 July 2017

title

Infusional 5-fluorouracil, cisplatin and mitomycin C in advanced gastric cancer: a low cost effective regimen (English)

1 reference

25 July 2017

1 reference

1 reference

R Labianca

12

0 references

Stefano Cascinu

object named as

S Cascinu

1

0 references

author name string

A M Baldelli

2

1 reference

25 July 2017

V Catalano

3

1 reference

25 July 2017

P Giordani

4

1 reference

25 July 2017

G D Beretta

5

1 reference

25 July 2017

R R Silva

6

1 reference

25 July 2017

G Gasparini

7

1 reference

25 July 2017

D Mari

8

1 reference

25 July 2017

R Maisano

9

1 reference

25 July 2017

S Salvagni

10

1 reference

25 July 2017

S Barni

11

1 reference

25 July 2017

L Frontini

13

1 reference

25 July 2017

C Curti

14

1 reference

25 July 2017

G Catalano

15

1 reference

25 July 2017

language of work or name

English

0 references

publication date

1 January 2002

1 reference

British Journal of Cancer

25 July 2017

published in

1 reference

25 July 2017

volume

86

1 reference

25 July 2017

issue

2

1 reference

25 July 2017

page(s)

213-217

1 reference

Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trial

25 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375188

A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375188

Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO).

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375188

Intensive weekly chemotherapy for locally advanced gastric cancer using 5-fluorouracil, cisplatin, epidoxorubicin, 6S-leucovorin, glutathione and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375188

A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375188

Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin, glutathione, and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375188

Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375188

Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375188

Mitomycin therapy in gastric cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375188

A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF).

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375188

Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375188

Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375188

Optimal two-stage designs for phase II clinical trials

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375188

Mechanisms to improve chemotherapy effectiveness

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375188

Cisplatin therapy for adenocarcinoma of the stomach.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375188

Combination chemotherapy with cisplatin and 5-fluorouracil 5-day infusion in the therapy of advanced gastric cancer: A Phase II trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2375188

Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.

21 June 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6600046

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6600046

Weekly 24-hour infusion of high-dose 5-fluorouracil plus folinic acid in combination with mitomycin C for the treatment of advanced gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6600046

A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer

21 January 2018

1 reference

12 December 2020

Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the

1 reference

12 December 2020

A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer

1 reference

12 December 2020

A phase II trial of 5-fluorouracil and high-dose intravenous leucovorin in gastric carcinoma

1 reference

12 December 2020

Neoadjuvant chemotherapy in locally advanced gastric carcinoma--a phase II trial with combined continuous intravenous 5-fluorouracil and bolus cisplatinum

1 reference

12 December 2020

Chemotherapy of gastric cancer

1 reference

12 December 2020

Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study

1 reference

12 December 2020

Weekly infusional 5-fluorouracil plus/minus other drugs for the treatment of advanced gastric cancer

1 reference

12 December 2020

Results of a randomised trial comparing ECF with MCF in advanced oesophago-gastric cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6600046

7 January 2021

inferred from DOI database lookup

Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6600046

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1038/SJ.BJC.6600046

1 reference

Dimensions Publication ID

25 July 2017

0 references

1 reference

25 July 2017

1 reference